Results: 3

Neoadjuvant chemotherapy with trastuzumab in HER2-positive breast cancer: pathologic complete response rate, predictive and prognostic factors

Braz. j. med. biol. res; 50 (2), 2017
The purpose of this study was to retrospectively review the pathologic complete response (pCR) rate from patients (n=86) with stage II and III HER2-positive breast cancer treated with neoadjuvant chemotherapy at our institution from 2008 to 2013 and to determine possible predictive and prognostic factors...

Eficacia y seguridad de fulvestrant en pacientes con cáncer de mama metastásico con receptores hormonales positivos, no tributarios a quimioterapia, que ha progresado a inhibidores de aromatasa no esteroideos

INTRODUCCIÓN: Antecedentes: El presente informe expone la evaluación de eficacia y seguridad del uso de fulvestrant en el manejo de pacientes post-menopáusicas, con diagnóstico de cáncer de mama metastásico con receptores hormonales positivos, progresivo a inhibidores de aromatasa no esteroideos co...

Hormonal receptors in mammary carcinoma: comparison between quantitative and qualitative methods

Säo Paulo med. j; 115 (4), 1997
Alternatives to the traditional hormone receptor dosages for prognostic evaluation and clinical approach to breast cancer have been proposed for immunohistochemical determinations. For correlation purposes, such procedures were compared in 37 patients presenting 5 to 15 years of survival. Considering 30 ...